In a significant move to enhance its manufacturing capabilities, White Raven Biopharma has partnered with Cytiva to integrate the latter's single-use bioreactor technology into its production facility in Belgium. This collaboration aims to increase the site's output by up to 50%, allowing White Raven to meet growing demand for its therapeutic proteins and monoclonal antibodies. The Cytiva XDR™ single-use bioreactors offer enhanced flexibility, enabling White Raven to produce both small and large-scale batches with ease, reducing time-to-market for new products. Additionally, the implementation of Cytiva's technology will enable White Raven to maintain product quality while minimizing contamination risks, ultimately ensuring that patients receive safe and effective treatments. With this strategic expansion, White Raven is poised to strengthen its position as a leading player in the biopharmaceutical industry.
NOTICE: The story and image of this article are completely ‘hallucinated’ by AI systems, based purely on the title of a real article found on the internet. Names, countries, people, … are purely used on coincidence and chosen by the AI, and are not to be taken seriously.